The landmark trial using cemiplimab as PD-1 blockade in advanced cSCC was reported in 2018, showing a 48.2% overall response rate.6 This study included 64 (75.3%) patients ≥65 years of age (median age 71–73), but excluded those with significant immunosuppression or recent systemic therapy for autoimmune disease. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.